TOMAS J. HEYMAN

Corporate Board Profile

Tech Score: 0/100

EXELIXIS, INC.

Filing Date	Source Excerpt
2024-04-18	Tomas J. Heyman has been a director since May 2023. Since 2021, Mr. Heyman has served as a consultant to Interlaken Therapeutics, Inc., a biotechnology company, and as its interim Chief Executive Officer, and since 2020, he has served as Operating Partner at Bioqube Ventures, a life sciences investment firm. Previously, Mr. Heyman served as the President of Johnson & Johnson’s Corporate Venture Capital Group, the venture capital arm of Johnson & Johnson, a pharmaceutical and consumer packaged goods company, from 2015 to 2019, and as the Global Head of Business Development for Johnson & Johnson’s Pharmaceutical Group from 1992 to 2015. In addition, he served as Managing Director of Janssen Pharmaceutica, a pharmaceutical NV, a pharmaceutical company and an affiliate of Johnson & Johnson (now known as Johnson & Johnson Innovative Medicine), from 2008 to 2016. Mr. Heyman began his career as a member of the legal department of Janssen Pharmaceutica NV in 1982. Mr. Heyman has served as Non-executive Chairman of the board of directors of Venatorx Pharmaceuticals, Inc., a privately held pharmaceutical company, since 2023. He has also served as a member of the board of directors of: Legend Biotech Corporation, a publicly held biotechnology company, since 2022; Xilio Therapeutics, Inc., a publicly held biotechnology company, since 2022 (and has announced his intention to not seek re-election in 2024); Invivyd, Inc. (formerly Adagio Therapeutics), a publicly held biopharmaceutical company, since 2021 (and has announced his intention to not seek re-election in 2024); OptiNose, Inc., a publicly held specialty pharmaceutical company, since 2020; and Akero Therapeutics, Inc., a publicly held biotechnology company, since 2020. Committee Assignments: Governance Committee, Risk Committee.

Filing Date

Source Excerpt

2024-04-18

Tomas J. Heyman has been a director since May 2023. Since 2021, Mr. Heyman has served as a consultant to Interlaken Therapeutics, Inc., a biotechnology company, and as its interim Chief Executive Officer, and since 2020, he has served as Operating Partner at Bioqube Ventures, a life sciences investment firm. Previously, Mr. Heyman served as the President of Johnson & Johnson’s Corporate Venture Capital Group, the venture capital arm of Johnson & Johnson, a pharmaceutical and consumer packaged goods company, from 2015 to 2019, and as the Global Head of Business Development for Johnson & Johnson’s Pharmaceutical Group from 1992 to 2015. In addition, he served as Managing Director of Janssen Pharmaceutica, a pharmaceutical NV, a pharmaceutical company and an affiliate of Johnson & Johnson (now known as Johnson & Johnson Innovative Medicine), from 2008 to 2016. Mr. Heyman began his career as a member of the legal department of Janssen Pharmaceutica NV in 1982. Mr. Heyman has served as Non-executive Chairman of the board of directors of Venatorx Pharmaceuticals, Inc., a privately held pharmaceutical company, since 2023. He has also served as a member of the board of directors of: Legend Biotech Corporation, a publicly held biotechnology company, since 2022; Xilio Therapeutics, Inc., a publicly held biotechnology company, since 2022 (and has announced his intention to not seek re-election in 2024); Invivyd, Inc. (formerly Adagio Therapeutics), a publicly held biopharmaceutical company, since 2021 (and has announced his intention to not seek re-election in 2024); OptiNose, Inc., a publicly held specialty pharmaceutical company, since 2020; and Akero Therapeutics, Inc., a publicly held biotechnology company, since 2020. Committee Assignments: Governance Committee, Risk Committee.

Data sourced from SEC filings. Last updated: 2026-02-03